Skip to main content
KIORA PHARMACEUTICALS INC logo

KIORA PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · KPRX ISIN · US49721T3095 LEI · 549300395G8DB8ZFV365 US Manufacturing
Open in API
Filings indexed 888 across all filing types
Latest filing 2026-05-28 Share Issue/Capital Cha…
Country US United States of America
Listing US KPRX

About KIORA PHARMACEUTICALS INC

https://kiorapharma.com/

Kiora Pharmaceuticals, Inc. is a clinical-stage company focused on developing advanced therapies for retinal diseases. The company's strategy is to target critical pathways underlying vision-threatening conditions using innovative small molecules. Its primary objective is to develop treatments that can slow, stop, or restore vision loss, with a particular focus on ophthalmic conditions that have limited or no effective therapies currently available.

Recent filings

Filing Released Lang Actions
424B3
Share Issue/Capital Change Classification · 75% confidence The document is a SEC prospectus filed pursuant to Rule 424(b)(3) (Registration No. 333-295994) detailing the registration and resale of 11,797,088 shares of common stock by selling stockholders. This is not an annual or interim report, earnings release, proxy, or management discussion. It is an offering document relating directly to the company’s share issuance/registration and capital structure. Hence, it best fits the “Share Issue/Capital Change” category (SHA).
2026-05-28 English
S-3
Regulatory Filings Classification · 90% confidence The document is a Form S-3 registration statement (prospectus) filed with the SEC under the Securities Act of 1933. It is an official regulatory filing (compliance document) rather than an annual or quarterly report, earnings release, or proxy statement. It does not belong to a more specific category (such as a capital markets press release) but is a primary SEC registration document. Therefore, it falls under the general “Regulatory Filings” category (RNS).
2026-05-18 English
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
Earnings Release Classification · 75% confidence The document is a Form 8-K “Current Report” under Item 2.02 “Results of Operations and Financial Conditions,” which furnishes a press release announcing quarterly financial results for the period ended March 31, 2026. It does not include full financial statements or detailed analysis, but rather a summary earnings press release. This matches the definition of an Earnings Release (ER). Q1 2026
2026-05-08 English
10-Q - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-08 English
ARS - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
Annual Report
2026-05-01 English
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 3, 2026, by Kiora Pharmaceuticals, Inc. It details a private placement financing transaction including issuance of common stock and warrants, terms of the securities, and related agreements. The content focuses on capital raising activities and securities issuance, which aligns with updates on company financing activities. It is not an annual or quarterly report, audit report, earnings release, or other types of filings. The detailed description of the securities purchase agreement and private placement clearly indicates this is a Capital/Financing Update filing. The document length is over 11,000 characters and contains substantive information about the financing event, not just an announcement or reference to a report, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-04-07 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.